Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Outlook Therapeutics (OTLK) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Outlook Therapeutics (OTLK) over the last 7 years, with Q3 2025 value amounting to 18863.9%.

  • Outlook Therapeutics' EBITDA Margin changed N/A to 18863.9% in Q3 2025 from the same period last year, while for Dec 2025 it was 4169.6%, marking a year-over-year change of. This contributed to the annual value of 4744.25% for FY2025, which is 70155200.0% down from last year.
  • According to the latest figures from Q3 2025, Outlook Therapeutics' EBITDA Margin is 18863.9%.
  • Outlook Therapeutics' 5-year EBITDA Margin high stood at 18863.9% for Q3 2025, and its period low was 1046.2% during Q2 2025.